Journal article
Enhanced solubility, permeability and anticancer activity of vorinostat using tailored mesoporous silica nanoparticles
AK Meka, LJ Jenkins, M Dàvalos-Salas, N Pujara, KY Wong, T Kumeria, JM Mariadason, A Popat
Pharmaceutics | MDPI | Published : 2018
Open access
Abstract
Suberoylanilide hydroxamic acid (SAHA) or vorinostat (VOR) is a potent inhibitor of class I histone deacetylases (HDACs) that is approved for the treatment of cutaneous T-cell lymphoma. However, it has the intrinsic limitations of low water solubility and low permeability which reduces its clinical potential especially when given orally. Packaging of drugs within ordered mesoporous silica nanoparticles (MSNs) is an emerging strategy for increasing drug solubility and permeability of BCS (Biopharmaceutical Classification System) class II and IV drugs. In this study, we encapsulated vorinostat within MSNs modified with different functional groups, and assessed its solubility, permeability and ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by a Project Grant (GNT1107836) from The National Health and Medical Research Council's (NHMRC), an NHMRC Early Career Fellowship and Career Development Fellowship to Amirali Popat and a NHMRC Senior Research Fellowship (GNT104692) to JMM. We would also like to thank Centre of Microscopy and Microanalysis as UQ for providing facilities to conduct TEM and XRD.